Introduction {#Sec1}
============

T1 carcinoma of the urinary bladder is a heterogeneous disease with potentially aggressive behavior leading to lethality \[[@CR1]\]. Indeed, despite sharing many of the genetic and epigenetic factors of muscle-invasive bladder cancer, it is classified as non-muscle invasive. Yet, patients with T1 bladder cancer have an overall mortality of 33% and a cancer-specific mortality of 14% at three years after diagnosis, suggesting that these patients have a high risk of disease progression and, accordingly, require meticulous surgery, endoscopic surveillance and informed clinical decision-making \[[@CR2]\].

The variability in the outcomes of patients with T1 bladder cancer is a result of both tumor heterogeneity and pathological staging, as well as inconsistencies in risk stratification, endoscopic resection and schedules of delivery of BCG \[[@CR3]\]. Owing to limitations in clinical staging, patients with T1 bladder cancer are at risk of both under-treatment with use of BCG despite recurrence, and overtreatment with early radical cystectomy. Understanding the pathologic features of T1 bladder cancers and how they impact prognosis and, therefore, could improve risk stratification to align therapy with biological risk and clinical behavior of the individual tumor \[[@CR4], [@CR5]\]. While novel prognostic features such as variant histology and lymphovascular invasion have been included in the clinical decision-making, more features are needed to improve our prognostic accuracy \[[@CR5]--[@CR7]\].

There is a growing evidence that tumor depth and extension could be such a feature for patients with T1(or pT1) bladder cancer \[[@CR8], [@CR9]\]. To test this hypothesis, we performed a systematic review and meta-analysis to evaluate the value of T1(or pT1) substaging for predicting oncological outcomes in patients with T1(or pT1) urothelial carcinoma of the bladder. T1 and pT1 were referred to disease stage in patients who underwent trans-urethral resection of bladder tumor (TURBT) and radical cystectomy, respectively.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

A full electronic literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted by two independent authors on March 2019 to find relevant studies for this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines \[[@CR10]\]. The search terms used were ("T1" OR "T1a" OR "T1b" OR "T1 m" OR "T1e" OR "muscularis mucosa invasion" OR "subclassification" OR "substage" OR "substaging") AND ("bladder cancer" OR "bladder carcinoma" OR "bladder neoplasm"). The protocol for this systematic review was registered in PROSPERO (Prospective Register of Systematic Reviews, CRD42019129661) and is available in full on the University of York website.

Inclusion criteria {#Sec4}
------------------

The following criteria were considered to select eligible studies: prospective or retrospective studies including full text regarding T1(or pT1) substaging in patients with non-muscle-invasive bladder cancer (NMIBC) with oncological outcomes including disease recurrence (DR) and disease progression (DP). We excluded studies in other than English, meeting abstract, case reports, review articles, replies, expert opinions, and comment letters.

Data extraction {#Sec5}
---------------

Data were extracted on first author, year of publication, patients, region of study, recruitment period, study design, total number of T1(or pT1) patients, number of substaged T1(or pT1) patients, substaging system, patients' age, and follow-up duration. Oncological outcomes including DR and DP were the primary outcomes of interest. DR was defined as histological detection of bladder cancer and DP was defined as development of muscle-invasive disease or distant metastasis after primary treatment. Two independent reviewers assessed all full text studies and excluded inappropriate ones after screening based on the study title and abstract. The muscularis mucosa (MM) invasion substaging was defined as T1a/b (or pT1a/b) or T1a/b/c (or pT1a/b/c). According to the T1a/b (or pT1a/b) staging, T1a (or pT1a), where tumors cells invade the lamina propria but are still located above the level of the MM and T1b (or pT1b), where tumors cells are seen invading into or beyond the MM. In T1a/b/c (or pT1a/b/c) staging system, T1a (or pT1a) was defined as invasion into the stroma but not to MM, T1b (or pT1b); invasion into MM but not beyond MM, and pT1c (or pT1c); invasion beyond the MM but not to muscularis propria. Infiltration depth substaging system was defined as T1 m/e (or pT1 m/e). T1 m, or pT1 m (micro infiltration) was a single focus of lamina propria invasion with a maximum depth of 0.5 mm (within one high power field; objective × 40). T1e or pT1/e (extensive infiltration) was defined as a larger area with invasion or multiple micro-invasive areas.

Statistical analyses {#Sec6}
--------------------

We extracted reported HRs and 95%CIs to calculate cumulative effect size of studies which presented the association between T1(or pT1) substaging and DR and DP. Studies presented HR using multivariate Cox proportional hazard regression model were included in meta-analysis. STATA/MPTM, version 14.2 (Stata-Corp., College Station, TX, USA) was used to perform meta-analysis. Heterogeneity between the studies included in the meta-analysis was assessed by Cochrane *Q* test and I^2^ statistics. An I^2^ \> 50% and *p* value \< 0.05 in Cochrane *Q* test implied that the heterogeneity existed. With no heterogeneity among selected studies, we considered fixed effect models to calculate pooled HRs. In case of significant heterogeneity, we used random effect model. Visual inspection of funnel plot was carried out to identify publication bias in our meta-analysis.

Risk of bias (RoB) assessment {#Sec7}
-----------------------------

The RoB assessment of each study was done according to the Cochrane Handbook for Systematic Reviews of Interventions for including nonrandomized studies \[[@CR11], [@CR12]\]. The confounding factors including treatment modality, tumor grade, carcinoma in situ (CIS), multifocality, T1 (or pT1) substaging, and tumor size were identified as the most important prognostic factors. The presence of confounders was determined by consensus. The RoB assessment for each study was performed by two independent authors and the overall RoB level was presented as "low", "intermediate", or "high" risk.

Results {#Sec8}
=======

Literature search process {#Sec9}
-------------------------

A total of 4999 studies were found after an initial search; 3036 records remained after exclusion of duplicates (Fig. [1](#Fig1){ref-type="fig"}). After exclusion of non-relevant studies, review articles, case reports, comments, replies, meeting abstracts, and studies in other than English, 57 studies remained. Finally, 36 and 12 studies were included for qualitative and quantitative evidence synthesis, respectively.Fig. 1PRISMA flow chart for article selection process to analyze the prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma

Characteristics of the included studies {#Sec10}
---------------------------------------

Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} summarize the studies' characteristics and patients' clinical data, respectively. Four studies were designed prospectively \[[@CR13]--[@CR16]\] and 32 studies were retrospective in design \[[@CR8], [@CR9], [@CR17]--[@CR46]\]. All studies were published between 1994 and 2018. In total, 6781 patients were included in 36 studies with 5964 patients who underwent T1 (or pT1) substaging and outcomes analysis. Twenty-three studies came from Europe, five from North America, six from Asia, and two from Europe/Canada region.Table 1Study characteristics of 40 studies assessing the prognostic value of T1 substaging in patients with bladder urothelial carcinomaAuthorYearRegionRecruitment periodDesignNo.pT1 PtsSubstaged T1 PtsSubstaging systemOncological end pointHasui \[[@CR23]\]1994Japan1980--1991Retrospective8888MM invasion (T1a/T1b)DR, DPHolmäng \[[@CR24]\]1997Sweden1987--1988Retrospective121113MM invasion (T1a/T1b)DP, CSS, OSSmits \[[@CR40]\]1998The Netherlands1987--1990Retrospective133124MM invasion (T1a/T1b/T1c)DR, DPCheng \[[@CR22]\]1999USA1987--1992Retrospective8383Depth of lamina propria invasionDPKondylis \[[@CR26]\]2000USA1981--1997Retrospective5549MM invasion (T1a/T1b)DR, DPShariat \[[@CR39]\]2000USAN/ARetrospective4736MM invasion (T1a/T1b)DR, DP, OSBernardini \[[@CR17]\]2001France1973--1996Retrospective14994MM invasion (T1a/T1b)PFSSozen \[[@CR42]\]2002Turkey1983--1997Retrospective9050MM invasion (T1a/T1b)DR, DPOrsola \[[@CR32]\]2005Spain1996--2001Retrospective9785MM invasion (T1a/T1b/T1c)RFS, PFSvan der Aa \[[@CR45]\]2005The NetherlandsN/ARetrospective6353Tumor infiltration depth (T1 m/T1e)DPChaimuangraj \[[@CR20]\]2006Thailand1990--2004Retrospective192192Muscularis mucosa invasionDRAndius \[[@CR13]\]2007Sweden1987--1988Prospective121121MM invasion (T1a/T1b)^†^PFS, CSSMhawech-Fauceglia \[[@CR29]\]2007SwitzerlandN/ARetrospective4545MM invasion (T1a/T1b)DR, DPQueipo-Zaragoza \[[@CR37]\]2007Spain1986--2003Retrospective9183MM invasion (T1a/T1b)DPSoukup \[[@CR16]\]2008Czech Republic2001--2005Prospective10599MM invasion (T1a/T1b)DR, DP (PFS)Orsola \[[@CR14]\]2010SpainN/AProspective159138MM invasion (T1a/T1b)DR, DPBertz \[[@CR18]\]2011Germany1989--2006Retrospective309309MM invasion (T1a/T1b), Infiltration depth (≤ 1 HPF/\> 1 HPF)CSS, RFS, PFSPalou \[[@CR34]\]2012Spain/Belgium1985--1996Retrospective14693MM invasion (T1a/T1b/T1c)DR, DP, CSMLee \[[@CR27]\]2012Korea1999--2009Retrospective183183MM invasion (T1a/T1b/T1c)DR, DP, CSMChang \[[@CR21]\]2012Taiwan1991--2005Retrospective509509Muscularis mucosa invasion, Infiltration depth (3 cut-off values to substage the T1 tumors: 0.5 mm, 1.0 mm, and 1.5 mm)DR, DP, CSD, OMvan Rhijn \[[@CR46]\]2012The Netherlands/Canada1984--2006Retrospective129129MM invasion (T1a/T1b/T1c), tumor infiltration depth (T1 m/T1e)DR, DPBrimo \[[@CR19]\]2013Canada2004--2012Retrospective8686Muscularis mucosa invasion, Maximum tumor depth (mm)DR,DP,WFSOlsson \[[@CR31]\]2013Sweden1992--2001Retrospective285211MM invasion (T1a/T1b/T1c)DR, DPNishiyama \[[@CR30]\]2013Japan1995--2010Retrospective7979Tumor infiltration depth (T1 m/T1e)DR, DPRouprêt \[[@CR38]\]2013France1994--2010Retrospective612587MM invasion (T1a/T1b)RFS, PFS, CSSSoukup \[[@CR41]\]2014Czech Republic2002--2009Retrospective200176MM invasion (T1a/T1b)RFS, PFS, CSS, OSHu \[[@CR25]\]2014USA1997--2005Retrospective3923Focality, Percentage of tumor invasion, and aggregate length of invasionDRD. E. Marco \[[@CR44]\]2014Italy2000--2006Retrospective4040MM invasion (T1a/T1b/T1c), tumor infiltration depth (T1 m/T1e)CSS, DPLim \[[@CR28]\]2015Korea1998--2012Retrospective177141MM invasion (T1a/T1b/T1c)RFS, PFSOrsola \[[@CR15]\]2015SpainN/AProspective200200MM invasion (T1a/T1b)DR, DPPatschan \[[@CR36]\]2015Sweden1997--2003Retrospective167152MM invasion (T1a/T1b/T1c)PFSPatriarca \[[@CR35]\]2016Italy2011--2007Retrospective450314MM invasion (T1a/T1b), tumor infiltration depth (T1 m/T1e), ROL substaging^†^DR, DPColombo \[[@CR8]\]2018Italy2007--2011Retrospective502250MM invasion (T1a/T1b/T1c), microinfiltration and extended infiltration of LP (T1 m/T1e), ROL substagingDR, DPFransen van de Putte \[[@CR9]\]2018Europe/Canada1982--2010Retrospective601601MM invasion (T1a/T1b), microinfiltration and extended infiltration of LP (T1 m/T1e)PFS, CSSOtto \[[@CR33]\]2018Germany/The Netherlands1989--2012Retrospective322322Metric T1 substage (tumor infiltration depth)PFS, CSS, OSTuran \[[@CR43]\]2018Turkey2009--2014Retrospective106106MM invasion (T1a/T1b), tumor infiltration depth (T1 m/T1e)DR, DP*N/A* not available, *LP* lamina propria, *MM* muscularis mucosa, *PFS* progression-free survival, *CSM* cancer-specific mortality, *CSS* cancer-specific survival, *OS* overall survival, *WFS* worsening-free survival, *DR* disease recurrence, *DP* disease progression, *RFS* recurrence-free survival, *OM* overall mortality, *HPF* high power field^†^ROL substaging ROL1 \< 1 power field (objective 20×, ocular 10×/field 22, diameter 1.1 mm) of invasion, approximately corresponding to invasion of the lamina propria 1 mm thick or less; ROL2: \> 1 power field (objective 20×), approximately corresponding to invasion of the lamina propria more than 1 mm thick, or multifocal invasion with foci cumulatively amounting to invasion of the lamina propria more than 1 mm thickTable 2Patient characteristics in 40 studies assessing the prognostic role of T1 substaging in patients with bladder urothelial carcinomaAuthorAge, year (range)Independent correlation with oncologic outcomesFollow-up durationHasui \[[@CR23]\]Mean: 68 (37--95)SN/AHolmäng \[[@CR24]\]Mean: 73.1 (48--97)S (for DP and CSS)≥ 5 yearsSmits \[[@CR40]\]N/AS (for PFS)Minimal follow-up: 3 yearsCheng \[[@CR22]\]Mean: 71 (47--94)SMean: 5.2 years (range, 1 day--10.4)Kondylis \[[@CR26]\]N/ANSMedian 71 months (range, 4--147)Shariat \[[@CR39]\]Median: 67 (30--86)NSMedian: 79 monthsBernardini \[[@CR17]\]Mean: 68.9 (42--90)SMean: 64.9 months (range, 5--288)Sozen \[[@CR42]\]Median: 62 (33--84)SMean: 68 months (range, 24--120)Orsola \[[@CR32]\]Mean: 66.4(30.3--86.8)S (in T1b/c vs T1a substaging for RFS and PFS)Mean: 53 monthsvan der Aa \[[@CR45]\]Mean: 68 (47--90)SMedian: 55 months (range, 9--228)Chaimuangraj \[[@CR20]\]Mean: 60 (43--83)SN/AAndius \[[@CR13]\]Median: 74 (48--98)NSMedian: 15 years for alive casesMhawech-Fauceglia \[[@CR29]\]Mean: 70S (for DP)Median: 12 monthsQueipo-Zaragoza \[[@CR37]\]Mean: 68.1SMean: 57.8 months (range, 13--24)Soukup \[[@CR16]\]Mean: 68.43 (38--87)S (for PFS)Mean: 23.31 monthsOrsola \[[@CR14]\]Mean: 69S (for DP)Median: 20.3 monthsBertz \[[@CR18]\]Median: 71.7 (38--87 years).S (in Infiltration depth: ≤ 1 HPF vs \> 1 HPF for RFS and PFS)Mean: 49 months (range, 5--172)Palou \[[@CR34]\]Mean: 64.9 (25--81)NSMedian: 8.7 yearsLee \[[@CR27]\]Mean: 63.5 years (27--93)S (for DP and CSM)Mean: 43.5 months (range, 12--146)Chang \[[@CR21]\]Mean: 71 (23--92)S (MM invasion: S for DP, CSM, and OM) (depth of high-grade tumor: S for DR, DP, CSM, OM)Mean: 88 months (range, 1--240) for patients who were aliveMean: 39 months (range, 1--193) for patients who diedvan Rhijn \[[@CR46]\]Mean: 68.8S (in T1 m/T1e for DP)Median: 6.5 yearsBrimo \[[@CR19]\]Mean: 71SMean: 29 monthsOlsson \[[@CR31]\]Median: 74S (in T1b/c vs T1a substaging for DP in patients older than 73 years)Median: 60 monthsNishiyama \[[@CR30]\]Mean: 68.5S (for DR)Mean: 74.0 monthsRouprêt \[[@CR38]\]Median: 70SMean: 44 months (range, 6--161)Soukup \[[@CR41]\]Median: 68.83 (17.55--86.94)S (for PFS, CSS, OS)Median: 3.13 years (0.1--10.5)Hu \[[@CR25]\]Mean: 70 years (56--94)S (in aggregate length of invasion; \> 0.5 cm)N/AD. E. Marco \[[@CR44]\]Mean: 69.9NSMedian: 9.5 yearsLim \[[@CR28]\]Mean: 68.9 (20--93)S (for PFS)Mean: 73.3 months (range, 3.9--187.9)Orsola \[[@CR15]\]Median: 71S (for DP)Median: 71 months (range: 5--107)Patschan \[[@CR36]\]Median: 74NS(3 years follow-up in analysis)Patriarca \[[@CR35]\]Mean: 71.3 (64--79)S (in ROL1 VS ROL 2 substaging for DP)Mean: 46 monthsColombo \[[@CR8]\]Mean: 70 (64--77)S (for DP in ROL2 vs ROL1 substaging)Median: of 60 monthsFransen van de Putte \[[@CR9]\]Median: 71S (for PFS and CSS in T1e vs T1 m substaging)Median: 5.9 yearsOtto \[[@CR33]\]Median: 72NSMedian: 42 monthsTuran \[[@CR43]\]Mean: 67.9S (in T1a/b substaging for DR)Mean: 54 months*N/A* not available, *S* significant, *NS* non-significant, *MM* muscularis mucosa *PFS* progression-free survival, *CSM* cancer-specific mortality, *CSS* cancer-specific survival, *OS* overall survival, *OM* overall mortality, *DR* disease recurrence, *DP* disease progression, *RFS* recurrence-free survival, *HPF* high power field^†^*S* statistical significance *p* value \< 0.05

Nine studies included patients who had been substaged with both MM and tumor infiltration depth staging systems. Twenty-two studies included MM invasion substaging system only and five included patients substaged with tumor infiltration depth staging system only. TURBT with or without intravesical BCG or chemotherapy agents was reported as initial therapy in 6677 patients. Radical or partial cystectomy and/or radiation therapy were reported in 104 patients as initial therapeutic modality \[[@CR13], [@CR17], [@CR24], [@CR29], [@CR35], [@CR39], [@CR45]\]. The prognostic value of T1(or pT1) substaging on at least one oncological outcome was established in 29 studies.

Meta-analysis {#Sec11}
-------------

### T1 (or pT1) MM invasion substaging and DP {#Sec12}

The impact of MM invasion on DP was investigated in patients with T1(or pT1) bladder urothelial carcinoma. Overall seven studies with a total of 899 patients were identified and MM invasion was associated with a higher DP rate (pooled HR 2.61, 95%CI: 1.61--4.23) (Fig. [2](#Fig2){ref-type="fig"}A) \[[@CR16], [@CR19], [@CR27], [@CR28], [@CR32], [@CR41], [@CR46]\]. A statistically significant heterogeneity was found among included studies using the Chi-square and *I*^2^ tests (I\^2 = 54.1%, *p* = 0.042); the weights were from random effect model to analyze pooled HR. Funnel plots identified one study over the pseudo 95%CI (Fig. [2](#Fig2){ref-type="fig"}A).Fig. 2**A** Forest plots and funnel plot of studies investigating the association of T1a/b/c substaging system with disease progression (DP) and disease recurrence (DR) outcomes. **B** T1a/b/c substaging system RoB table, **a** Random sequence generation (selection bias). **b** Allocation concealment (selection bias). **c** Blinding of participants and personnel (Performance bias.). **d** Blinding of outcome assessment (detection bias). **e** Incomplete outcome data (attrition bias). **f** Selective reporting (reporting bias); and adjustment for the effects of the following confounders. **g** Treatment modality. **h** Tumor grade. **i** CIS. **j** Multifocality. **k** T1 m/e substaging. **l** Tumor size. Green circles: low risk of bias and confounding, red circles: high risk of bias and confounding, yellow circles: unclear risk of bias and confounding. *CI* confidence interval, *HR* hazard ratio

### T1 (or pT1) MM invasion substaging and DR {#Sec13}

Six studies in a total of 930 patients reported HR to present the prognostic value of MM invasion on DR in T1(or pT1) urothelial bladder carcinoma patients \[[@CR16], [@CR18], [@CR19], [@CR27], [@CR40], [@CR46]\]. The overall pooled HR was 1.23 (95%CI: 1.01--1.49) implying a significant association between MM invasion and DR (Fig. [2](#Fig2){ref-type="fig"}A). The Chi-square and *I*^2^ tests did not show any significant heterogeneity (I\^2 = 41.4%, *p* = 0.129). Funnel plots revealed one study over the pseudo 95%CI (Fig. [2](#Fig2){ref-type="fig"}A). Figure [2](#Fig2){ref-type="fig"}B shows the RoB table of studies included in the T1(or pT1) MM invasion substaging meta-analysis.

### Infiltration depth substaging and DP {#Sec14}

Five studies with a total of 1171 patients with T1(or pT1) bladder urothelial carcinoma reported the association of tumor infiltration depth and DP \[[@CR9], [@CR18], [@CR30], [@CR45], [@CR46]\]. Tumor infiltration depth was associated with DP (pooled HR: 3.29, 95%CI: 2.39--4.51) (Fig. [3](#Fig3){ref-type="fig"}A). There was no significant heterogeneity in the Cochrane *Q* or *I*^2^ tests (I\^2 = 0.0%, *p* = 0.924). No study was detected over the pseudo 95%CI on Funnel plots (Fig. [3](#Fig3){ref-type="fig"}A).Fig. 3**A** Forest plots and funnel plot of studies investigating the association of T1 m/e substaging system with disease progression (DP) and disease recurrence (DR) outcomes. **B** T1 m/e substaging system RoB table, **a** Random sequence generation (selection bias). **b** Allocation concealment (selection bias). **c** Blinding of participants and personnel (Performance bias.). **d** Blinding of outcome assessment (detection bias). **e** Incomplete outcome data (attrition bias). **f** Selective reporting (reporting bias); and adjustment for the effects of the following confounders. **g** treatment modality. **h** tumor grade. **i** CIS. **j** Multifocality. **k** T1a/b/c substaging. **l** Tumor size. Green circles: low risk of bias and confounding, red circles: high risk of bias and confounding, yellow circles: unclear risk of bias and confounding. *CI* confidence interval, *HR* hazard ratio

### Infiltration depth substaging and DR {#Sec15}

The impact of infiltration depth on DR was investigated in three studies in a total of 517 patients with T1(or pT1) bladder urothelial carcinoma \[[@CR18], [@CR30], [@CR46]\]. There was a significant association between infiltration depth and DR with pooled HR of 1.49 (95%CI: 1.11--2.00) (Fig. [3](#Fig3){ref-type="fig"}A). The Chi-square and *I*^2^ tests did not show any significant heterogeneity (I\^2 = 56.4%, *p* = 0.101). Funnel plots identified no study over the pseudo 95%CI (Fig. [3](#Fig3){ref-type="fig"}A). Figure [3](#Fig3){ref-type="fig"}B shows the RoB table of studies included in T1(or pT1) Infiltration depth substaging meta-analysis.

Discussion {#Sec16}
==========

In this systematic review and meta-analysis, we assessed the prognostic value of T1(or pT1) substaging systems on oncological outcomes in patients with T1(or pT1) bladder urothelial carcinoma. Both MM invasion and tumor infiltration depth substaging systems were strongly associated with both DR and DP after adjusting for the effects of established confounding factors (e.g., tumor grade, CIS, and multifocality).

The most widely used prognostic tools, taking into account tumor grade and stage, prior recurrences, tumor size, multifocality, and the presence of CIS, are still suboptimal to predict DR and DP. Moreover, the lack of effective bladder cancer information among general public may be as an important factor affecting patients' outcomes and online information and social media could be effective to improve quality of patient's care and disease management in patients with bladder cancer \[[@CR47]\].

We and others have shown that the current prognostic and risk stratification tools are too inaccurate to guide clinical decision making safely \[[@CR1], [@CR48], [@CR49]\]. In this review and meta-analysis, we confirm that tumor invasion into MM and tumor infiltration depth of more than 0.5 mm are strong predictors of disease recurrence and progression and could be used to distinguish high risk patients for recurrence and progression who might benefit from standard adjuvant therapy (e.g., intravesical immunotherapy or chemotherapy). From these who are most likely to benefit from intensification of care such as early radical cystectomy.

In patients with NMIBC, the probability of disease progression can be as high as 45% at five years \[[@CR50]\]. Although it has been suggested that MM substaging might be helpful to identify high risk patients who are likely to suffer from disease progression despite adequate intravesical therapy, available data quality has not been of high quality and prognostic tools have not included this valuable parameter \[[@CR38], [@CR51]\]. Martin-Doyle et al. evaluated the prognosticators to improve selection criteria for early cystectomy in patients with high-grade T1 bladder cancer in a meta-analysis. The authors reported T1a/b substaging system as a valuable prognosticator of oncological outcomes comparable with our study with pooled HR of 1.81 (95%CI: 0.88--3.73) for DR and pooled HR of 3.55 (95%CI: 1.92--6.56) for DP in 420 and 785 patients with high-grade T1 bladder cancer, respectively \[[@CR51]\]. We confirmed that both MM invasion and tumor infiltration depth are strong predictors of disease progression after controlling for the effect of standard prognosticators. Indeed, patients harboring T1b/c or T1e in substaging system may benefit from early radical cystectomy as their tumor carries the biologic and clinical behavior of muscle-invasive bladder cancer \[[@CR51]\]. In patients considered candidates for radical cystectomy, pretreatment imaging modalities including magnetic resonance imaging and positron emission topography/computed tomography (CT) provide higher sensitivity and similar specificity compared to CT for detection of positive lymph nodes that might have a significant impact on clinical decision-making process \[[@CR52]\].

A consensus among pathologists is urgent to propose T1(or pT1) substaging systems as a prognosticator in TNM classification system and guidelines. MM is identified in 12--83% of bladder biopsy specimen \[[@CR53], [@CR54]\]. Therefore, some studies proposed identification of large vessels of the vascular plexus as an alternative tumor extension marker in specimens without obvious MM \[[@CR43], [@CR46]\]. Moreover, although a cut-off point of 5 mm has been proposed in several studies to define tumor infiltration depth, other studies have utilized other definitions \[[@CR8], [@CR35]\]. These discrepancies between definitions may lead to low reproducibility and questionable validity. Standardization and prospective assessment in controlled studies is necessary.

According to our study, although substaging of T1(or pT1) disease is somewhat controversial and difficult to implement in all cases; the main advantage of this scoring system is to identify the high risk T1 bladder cancer patients who might benefit from more rigorous follow-up and ideally from more aggressive treatments which are appropriate for invasive bladder carcinoma.

This study is not without limitations. The majority of included studies in this systemic review were retrospective in design precluding robust conclusions about the prognostic value of T1(or pT1) substaging systems. Moreover, the heterogeneity of substaging systems was found in MM invasion and tumor infiltration depth systems as well as the outcomes assessed in the studies makes clear conclusions difficult. Indeed, further studies are needed to assess the prognostic value of T1(or pT1) substaging systems in patient counselling and risk-based selection of the personalized therapeutic modality.

Conclusion {#Sec17}
==========

We found that T1(or pT1) substaging systems are strong predictors of oncological outcomes (DR, DR). Although T1(or pT1) substaging systems are promising and can be used as an aid in determining the most appropriate treatment modality and intensity of follow-up, optimal T1(or pT1) substaging system definition remains to be elucidated in future well-designed prospective studies.
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